These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 23591553)

  • 1. Dopamine dysregulation syndrome in Parkinson's disease: from clinical and neuropsychological characterisation to management and long-term outcome.
    Cilia R; Siri C; Canesi M; Zecchinelli AL; De Gaspari D; Natuzzi F; Tesei S; Meucci N; Mariani CB; Sacilotto G; Zini M; Ruffmann C; Pezzoli G
    J Neurol Neurosurg Psychiatry; 2014 Mar; 85(3):311-8. PubMed ID: 23591553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subthalamic nucleus stimulation and compulsive use of dopaminergic medication in Parkinson's disease.
    Eusebio A; Witjas T; Cohen J; Fluchère F; Jouve E; Régis J; Azulay JP
    J Neurol Neurosurg Psychiatry; 2013 Aug; 84(8):868-74. PubMed ID: 23447648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus.
    De Gaspari D; Siri C; Landi A; Cilia R; Bonetti A; Natuzzi F; Morgante L; Mariani CB; Sganzerla E; Pezzoli G; Antonini A
    J Neurol Neurosurg Psychiatry; 2006 Apr; 77(4):450-3. PubMed ID: 16543520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Markers of impaired motor and cognitive volition in Parkinson's disease: Correlates of dopamine dysregulation syndrome, impulse control disorder, and dyskinesias.
    Hinkle JT; Perepezko K; Rosenthal LS; Mills KA; Pantelyat A; Mari Z; Tochen L; Bang JY; Gudavalli M; Yoritomo N; Butala A; Bakker CC; Johnson V; Moukheiber E; Dawson TM; Pontone GM
    Parkinsonism Relat Disord; 2018 Feb; 47():50-56. PubMed ID: 29198499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subthalamic stimulation in Parkinson's disease: restoring the balance of motivated behaviours.
    Lhommée E; Klinger H; Thobois S; Schmitt E; Ardouin C; Bichon A; Kistner A; Fraix V; Xie J; Aya Kombo M; Chabardès S; Seigneuret E; Benabid AL; Mertens P; Polo G; Carnicella S; Quesada JL; Bosson JL; Broussolle E; Pollak P; Krack P
    Brain; 2012 May; 135(Pt 5):1463-77. PubMed ID: 22508959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parkinson's disease progression at 30 years: a study of subthalamic deep brain-stimulated patients.
    Merola A; Zibetti M; Angrisano S; Rizzi L; Ricchi V; Artusi CA; Lanotte M; Rizzone MG; Lopiano L
    Brain; 2011 Jul; 134(Pt 7):2074-84. PubMed ID: 21666262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medical therapy and subthalamic deep brain stimulation in advanced Parkinson's disease: a different long-term outcome?
    Merola A; Rizzi L; Zibetti M; Artusi CA; Montanaro E; Angrisano S; Lanotte M; Rizzone MG; Lopiano L
    J Neurol Neurosurg Psychiatry; 2014 May; 85(5):552-9. PubMed ID: 23847290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Motor features and response to oral levodopa in patients with Parkinson's disease under continuous dopaminergic infusion or deep brain stimulation.
    Elia AE; Dollenz C; Soliveri P; Albanese A
    Eur J Neurol; 2012 Jan; 19(1):76-83. PubMed ID: 21645174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subthalamic Nucleus Deep Brain Stimulation Modulate Catecholamine Levels with Significant Relations to Clinical Outcome after Surgery in Patients with Parkinson's Disease.
    Yamamoto T; Uchiyama T; Higuchi Y; Asahina M; Hirano S; Yamanaka Y; Kuwabara S
    PLoS One; 2015; 10(9):e0138462. PubMed ID: 26394059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopamine dysregulation syndrome, impulse control disorders and punding after deep brain stimulation surgery for Parkinson's disease.
    Lim SY; O'Sullivan SS; Kotschet K; Gallagher DA; Lacey C; Lawrence AD; Lees AJ; O'Sullivan DJ; Peppard RF; Rodrigues JP; Schrag A; Silberstein P; Tisch S; Evans AH
    J Clin Neurosci; 2009 Sep; 16(9):1148-52. PubMed ID: 19553125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute psychotropic effects of bilateral subthalamic nucleus stimulation and levodopa in Parkinson's disease.
    Funkiewiez A; Ardouin C; Krack P; Fraix V; Van Blercom N; Xie J; Moro E; Benabid AL; Pollak P
    Mov Disord; 2003 May; 18(5):524-30. PubMed ID: 12722166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid resolution of dopamine dysregulation syndrome (DDS) after subthalamic DBS for Parkinson disease (PD): a case report.
    Knobel D; Aybek S; Pollo C; Vingerhoets FJ; Berney A
    Cogn Behav Neurol; 2008 Sep; 21(3):187-9. PubMed ID: 18797262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcome of young onset Parkinson's disease after subthalamic stimulation--a cross-sectional study.
    Tsai ST; Hung HY; Hsieh TC; Lin SH; Lin SZ; Chen SY
    Clin Neurol Neurosurg; 2013 Oct; 115(10):2082-7. PubMed ID: 23916724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Compulsive use of dopaminergic drug therapy in Parkinson's disease: reward and anti-reward.
    Evans AH; Lawrence AD; Cresswell SA; Katzenschlager R; Lees AJ
    Mov Disord; 2010 May; 25(7):867-76. PubMed ID: 20461804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management.
    O'Sullivan SS; Evans AH; Lees AJ
    CNS Drugs; 2009; 23(2):157-70. PubMed ID: 19173374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deep brain stimulation improves survival in severe Parkinson's disease.
    Ngoga D; Mitchell R; Kausar J; Hodson J; Harries A; Pall H
    J Neurol Neurosurg Psychiatry; 2014 Jan; 85(1):17-22. PubMed ID: 23843542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation.
    Ardouin C; Voon V; Worbe Y; Abouazar N; Czernecki V; Hosseini H; Pelissolo A; Moro E; Lhommée E; Lang AE; Agid Y; Benabid AL; Pollak P; Mallet L; Krack P
    Mov Disord; 2006 Nov; 21(11):1941-6. PubMed ID: 16972268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcome of subthalamic nucleus DBS in Parkinson's disease: from the advanced phase towards the late stage of the disease?
    Rizzone MG; Fasano A; Daniele A; Zibetti M; Merola A; Rizzi L; Piano C; Piccininni C; Romito LM; Lopiano L; Albanese A
    Parkinsonism Relat Disord; 2014 Apr; 20(4):376-81. PubMed ID: 24508574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preliminary evaluation of the DDS-PC inventory: a new tool to assess impulsive-compulsive behaviours associated to dopamine replacement therapy in Parkinson's disease.
    Cabrini S; Baratti M; Bonfà F; Cabri G; Uber E; Avanzi M
    Neurol Sci; 2009 Aug; 30(4):307-13. PubMed ID: 19513585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term impact on quality of life of subthalamic nucleus stimulation in Parkinson's disease.
    Lezcano E; Gómez-Esteban JC; Tijero B; Bilbao G; Lambarri I; Rodriguez O; Villoria R; Dolado A; Berganzo K; Molano A; de Gopegui ER; Pomposo I; Gabilondo I; Zarranz JJ
    J Neurol; 2016 May; 263(5):895-905. PubMed ID: 26964542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.